The development of noninvasive biomarkers that reflect the state of immunosuppression (IS) remains an unmet need in liver transplantation (LT). Torque Teno virus (TTV) is a highly prevalent, nonpathogenic DNA virus whose plasma levels may be associated with the immune status of the host. The aim of this study was to assess the role of TTV as a biomarker of IS in LT recipients. TTV DNA in plasma was quantified by real-time polymerase chain reaction at different time points during the first year after transplant in a prospectively followed cohort of 63 de novo LT recipients, and any correlation between TTV DNA and biopsy-proven acute cellular rejection (ACR) and opportunistic infections was then evaluated. In addition, TTV DNA was studied in 10 longterm LT recipients in monotherapy with tacrolimus, 10 tolerant recipients, and 10 healthy controls. TTV was detected in the plasma of all patients. Among the 63 LT recipients, 20 episodes of ACR were diagnosed, and there were 28 opportunistic infections, 26 of them being cytomegalovirus (CMV) infections. TTV viremia was significantly lower during ACR (4.41 versus 5.95 log 10 copies/mL; P = 0.002) and significantly higher during CMV infections (5.79 versus 6.59 log 10 copies/mL; P = 0.009). The area under the receiver operating characteristic curve of TTV viral load for the diagnosis of moderate ACR was 0.869, with a sensitivity and negative predictive value of 100%, respectively, for a cutoff point of 4.75 log 10 copies/mL. There were no statistically significant differences in TTV DNA in either longterm or tolerant patients and healthy controls. In conclusion, plasma TTV DNA levels are associated with immune-related events after LT and could constitute a potential biomarker of the state of IS during the first months after transplant.
Despite the great advances made in immunosuppression (IS) in the past decades, the incidence of acute cellular rejection (ACR) after liver transplantation (LT) is still approximately 21%-27%. (1, 2) In addition, IS therapy has significant adverse effects, including an increased risk of opportunistic infections, particularly during the first months following transplantation. Currently, the state of IS is evaluated using immunosuppressant levels as a surrogate marker. Other methods, such as the ImmuKnow assay, have not been completely validated. (3) Hence, there is growing interest in finding biomarkers that could help assess the grade of IS in LT recipients. (4) Torque Teno virus (TTV) is a nonenveloped DNA virus with a very high prevalence in humans and whose interaction with the host and its potential pathogen role are currently being investigated. (5) Indeed, an association between the TTV plasma viral load and the immune status of the host has been suggested. Some studies, albeit limited by small sample sizes, have found a higher TTV viral load in LT patients with more intense IS therapy. (6, 7) Moreover, the pretransplant TTV viral load has also been associated with a higher probability of developing ACR. (8) Importantly,
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the potential association between post-LT TTV DNA and the risk of either rejection or opportunistic infections has received scant attention. The aim of our study was to analyze TTV load at different time points during the first year after LT in a cohort of prospectively followed patients and to evaluate its association with the incidence of rejection and cytomegalovirus (CMV) infection. In addition, we also sought to assess TTV load in tolerant and longterm LT recipients.
Patients and Methods

patients
We conducted a retrospective study in a cohort of prospectively followed adult patients undergoing LT who had been included in a sample collection protocol. Exclusion criteria were living donor LT, combined liver-kidney transplantation, retransplantation, and infection with human immunodeficiency virus. Only patients followed for at least 3 months after LT with plasma samples collected and a liver biopsy confirming or ruling out rejection (either by protocol or for clinical indication) were included in this study.
We also selected 3 additional groups of patients. One group consisted of 10 individuals followed for 5 or more years after transplant with normal liver function tests who were receiving monotherapy with tacrolimus and had trough levels below 5 ng/mL. The second group consisted of 10 tolerant patients, defined as LT recipients without IS therapy for more than 12 months who maintained normal allograft function and normal histology. Finally, we included a group of 10 healthy control individuals.
patient FOllOW-up anD is regiMens
All LT recipients were managed by transplant hepatologists using standardized protocols throughout the follow-up. After their discharge from transplant episode, patients were visited at the outpatient clinic monthly for the first 3 months and then every 2 months thereafter during the first year. During this time the following clinical and analytical variables were recorded: episodes of rejection and infections; laboratory tests including liver function tests and biochemistry and hematology analyses; current IS therapy; and any hospitalizations. IS regimens were chosen based on their pretransplant liver status as determined by the ChildPugh classification. Child-Pugh A patients were given a double IS therapy consisting of tacrolimus or cyclosporine with target trough levels of 8-10 ng/mL or 150-300 ng/mL, respectively, plus a tapering dose of corticosteroids to be withdrawn at month 6 after LT. Child-Pugh B and C patients and those who underwent transplant due to acute liver failure received induction therapy with a single dose of basiliximab immediately after LT. In addition, they were administered a delayed start (day 5) of tacrolimus or cyclosporine with target trough levels of 5-8 ng/mL or 75-150 ng/mL, respectively, as well as mycophenolate mofetil (MMF) of 2000 mg daily, and a tapering dose of corticosteroids to be withdrawn at month 6 after LT. A low dose of corticosteroids (2.5-5 mg of prednisone) was maintained long term in those transplant recipients with an autoimmune disease. Trough levels of calcineurin inhibitors (CNIs) were measured on a regular basis. Immunosuppressant levels were recorded at the time points when the TTV load was assessed.
liver BiOpsies anD reJectiOn episODes
Liver biopsies were performed if clinically indicated when these criteria were met: aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, or direct bilirubin serum levels more than 2-fold above the upper limit of normal and in the absence of pathological findings in the abdominal ultrasound examinations that might explain such biochemical abnormalities. In addition, a per-protocol biopsy was performed at month 3 after LT in those patients in whom a clinically indicated biopsy had not been performed. All rejection episodes were biopsy-proven, and severity was defined by the rejection activity index (RAI) score. (9) Moderate (RAI 5-6) and severe (RAI >6) episodes were treated with steroid boluses (500 mg of methylprednisolone for 3 consecutive days), whereas mild episodes (RAI 3-4) were treated by increasing the dose and the current immunosuppressant levels.
prOpHYlaXis OF inFectiOns anD DeFinitiOn OF inFectiOus events
All patients received a presurgical dose of 2 g of ceftazidim plus 400 mg of teicoplanin. Prophylaxis for Pneumocystis jiroveci with trimetroprim-sulfamethoxazole (160 mg/800 mg) was administered every 48 hours during the first year after transplantation. Antifungal prophylaxis with oral nistatin was administered during the first month. (11) CMV infection was defined according to the guidelines proposed by Ljungman et al. (12) All patients were monitored weekly for CMV viral load for the first 2 months and at least monthly for 6 months after LT. CMV infection was defined as asymptomatic CMV DNA >1000 copies/mL. CMV disease was defined as positive CMV DNA plus viral syndrome or end-organ disease as confirmed by immunohistological findings. CMV infection was treated with oral valgancyclovir (900 mg twice daily) for 14 days or until levels were undetectable. CMV disease was treated with intravenous ganciclovir until quantitative nucleic acid amplification tests proved negative.
ttv Dna QuantiFicatiOn
Plasma samples were obtained at the following time points: before transplantation, at week 1, and at months 1, 3, 6, and 12 after transplant. Samples were stored at -80°C until use. Viral DNA was purified from 500 µL of plasma using the MagNA Pure 96 Instrument with the MagNA Pure 96 DNA and Viral NA Large-Volume Kit (Roche, Basel, Switzerland) and eluted in a final volume of 50 µL. TTV DNA was determined by TaqMan real-time polymerase chain reaction (PCR) using the primers and probes reported by Maggi et al. (13) and then synthesized by Biomers and the 7900HT Fast Real-Time PCR (Applied Biosystems, Foster City, CA) platform. Also, 20 µL of reaction mix were used for quantification: 5 µL of extracted DNA, 10 µL of PerfeCTa FastMix II ROX mastermix (Quanta Biosciences, Beverly, MA), and 0.04 µM of each primer and probe. The TTV DNA standard was designed according to a preserved viral sequence and used in serial dilutions with a known number of copies, ranging from 10 9 to 10 0 copies/ reaction. Each run included a positive control from a healthy volunteer and no template negative controls. Thermal cycling was started for 20 seconds at 95°C (hot start), followed by 40 cycles of 1 second at 95°C and 20 seconds at 60°C. Results were obtained in copies/mL and expressed as a logarithm of this quantity, ranging from 1 to 10 log 10 .
etHical issues
The study was performed in accordance with the Declaration of Helsinki and the E6 Good Clinical Practice Standards of the International Council for Harmonisation. All personal data were codified in accordance with the Organic Law 15/1999 of December 13 on the Protection of Personal Data in Spain. All study data were treated anonymously with restricted access by only authorized personnel for the purposes of the study. Patients undergoing LT signed an informed consent in order to participate in the sample collection protocol (HCP/2014/0863). Thus, plasma samples were obtained at the specified time points and stored in the local tissue bank (Institut d'Investigacions Biomediques August Pi i Sunyer). The informed consent explicitly allowed the use of the samples only for studies approved by the clinical research ethical committee of the Hospital Clinic of Barcelona. Approval for this particular study was obtained on October 18, 2017 (HCB/2017/0674). Longterm and tolerant patients and those in the healthy control group were properly informed about the study and provided written informed consent specifically for this study. 
statistical analYsis
Statistical analysis was performed using Stata version 13.0 (StataCorp, College Station, TX). Continuous variables were expressed as medians and interquartile ranges (IQRs). Categorical variables were expressed in absolute terms and proportions. Area under the curve (AUC) of TTV DNA through different time points was calculated for comparisons between groups. Nonparametric tests (Wilcoxon rank sum test and the Kruskal-Wallis test) were used to evaluate differences between groups, and the analysis of variance test for repeated measures was used for intraindividual parameter comparisons. Linear regression was used to assess any correlations between continuous variables. A P value < 0.05 was used to indicate statistical significance. For the analysis of diagnostic performance, sensitivity, specificity, predictive values, and receiver operating characteristic curve tests were measured, resulting in an AUC with a 95% confidence interval (CI).
Results
stuDY pOpulatiOn
There were 63 patients included who underwent LT between September 2014 and May 2017 and who met the inclusion criteria. The characteristics of the cohort are shown in Table 1 . Most patients were male, the median age of the cohort at LT was 57 years, and the main etiology of baseline liver disease was hepatitis C virus (HCV) infection, with decompensated cirrhosis being the most frequent indication of transplantation.
is anD ttv Kinetics
Patients who received a double IS protocol (CNI + prednisone) accounted for 23.8% of the cohort whereas the remaining patients received the triple IS protocol (reduced CNI + MMF + prednisone with basiliximab induction; Table 1 ). Fifteen (23.8%) patients received cyclosporine as CNI, whereas the rest received tacrolimus. The mean trough levels of tacrolimus were significantly higher in the double IS protocol (7.2 versus 6.4 ng/mL; P = 0.03), whereas there were no differences in cyclosporine trough levels between the 2 protocols (179.3 versus 177.7 ng/ mL, P = not significant). TTV DNA was present in 59 (93.7%) patients before LT (4.14 log 10 copies/mL; IQR, 3.42-5.08 log 10 copies/mL). After LT, TTV DNA was detected in the plasma of all individuals. TTV DNA progressively increased after LT, peaking at month 3 (7.01 log 10 copies/mL; IQR, 6.05-8.08 log 10 copies/mL) and then decreasing during months 6 and 12 ( Fig. 1) . The variation in TTV DNA levels during the first year after LT was statistically significant (P < 0.001). When comparing the AUC of TTV DNA median at each time point, patients who received triple IS had significantly higher viremia than those with double IS (P < 0.001). We did not find statistically significant differences in TTV viremia according to the type of CNI used as an immunosuppressant. No significant correlation was found between TTV DNA and trough levels in either CNI as assessed by linear regression.
reJectiOn episODes
A total of 20 episodes of rejection were diagnosed in 19 patients (1 of them had 2 events); all were biopsy-proven. Regarding timing, 5 episodes were NOTE: Data are given as n (%) or median (IQR).
diagnosed during the first week, 4 in month 1, 8 in month 3, and 3 at month 6. A total of 8 episodes were moderate and were treated with steroid boluses, and 12 were mild. Of these mild episodes, 4 were treated by increasing the current IS therapy, and the remaining 8 were diagnosed incidentally during the protocol biopsy with liver tests within the range of normality (subclinical rejection). In these latter patients, the IS treatment was continued without changes, but there was no reduction in the doses of corticosteroids as prescribed by the local protocol. There were no severe episodes of rejection. All episodes were recovered and no graft was lost because of rejection. There were no significant differences in the proportion of rejection episodes between patients receiving double or triple IS protocol (26.7% versus 31.2%, respectively; P = 0.73) or between recipients receiving tacrolimus or cyclosporine (31.9% versus 20.0%; P = 0.37). The proportion of moderate ACR episodes was also similar in both protocols (12.5% versus 13.2%). CNI trough levels did not vary significantly during rejection. No significant differences were found when we compared TTV DNA in the episodes of rejection (including all of them) with the remaining samples. However, when we only considered the clinical episodes of rejection (thus excluding episodes of subclinical rejection diagnosed by protocol biopsy), TTV DNA was significantly lower during ACR (4.41 versus 5.95 log 10 copies/mL; P = 0.002). In addition, TTV DNA was lowest in episodes of moderate rejection compared with mild rejection or absence of rejection (P = 0.003; Fig. 2A ). Those patients who developed moderate ACR during the first year had a near significantly lower cumulative viremia than those who did not (P = 0.06). 
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A total of 60 infectious events were recorded in 41 individuals in the cohort. Of these, 31 episodes were bacterial infections, which were more frequent soon after transplantation: 14 (45.2%) episodes at week 1 and 12 (38.7%) at month 1. The most prevalent origins of infection were the urinary tract, totaling 13 episodes, followed by the respiratory tract (6 episodes, 2 of them mechanical ventilation-associated pneumonia) and catheter-associated bacteriemia (4 episodes). Only 1 fungal infection was diagnosed, which was a urinary tract infection due to Candida albicans. Viral infections accounted for the remaining 28 events. Almost all of them were caused by CMV (except for 1 case of herpes virus 6 infection, and 1 case of influenza virus infection). Five patients developed CMV disease with organ involvement and need for hospitalization. Patients who received triple therapy had significantly more episodes of CMV infection than those who received double IS (50.0% versus 13.3%; P = 0.01), and all patients who had CMV disease received triple IS. Recipients with CMV serology mismatch (D+/R-) had significantly more episodes of CMV infection (64.2% versus 35.0%; P = 0.047), but there were no differences in their distribution between IS protocols (7.7% versus 26.8%; P = 0.15).
Considering that CMV infection is largely associated with IS, with other factors exerting considerably less impact than on the occurrence of fungal or bacterial infections, we investigated the relationship between TTV and CMV episodes. During episodes of CMV infection, TTV DNA was significantly higher (6.59 versus 5.79 log 10 copies/mL; P = 0.009) than during the rest of the time points. When we compared those patients who had CMV infection during the first year after LT with those who did not, cumulative TTV DNA was significantly higher in the first group (6.17 versus 5.67 log 10 copies/mL; P = 0.02). In fact, this difference was also significant when comparing the AUC of TTV DNA median at each time point (P = 0.047). During CMV disease, TTV DNA was also significantly higher (8.20 versus 5.85 log 10 copies/mL; P = 0.005). Patients with CMV disease had a significantly higher cumulative TTV viremia during the first year after LT (P = 0.005). When we compared samples without CMV, those with CMV infection, and those with CMV disease, differences were statistically significant (P = 0.005; Fig. 2B ). We did not find significant differences in TTV levels before transplant between patients with positive and negative serology for CMV (4.24 versus 4.14 log 10 ; P = 0.95). After transplant, a significantly higher cumulative TTV DNA load was found in the seronegative CMV group (6.37 versus 5.78 log 10 copies/mL; P = 0.01), though when stratifying by IS protocol, this difference was only significant in the triple IS protocol (6.52 versus 5.92 log 10 copies/ mL; P = 0.02), in agreement with a higher incidence of CMV infection in these patient groups. Finally, a potential correlation between TTV DNA and CMV DNA during episodes of infection was also analyzed using linear regression, although no significant association was found (r = 0.08; P = 0.13).
lOngterM assessMent OF ttv
Two groups of longterm transplanted patients were included for the purpose of exploring the TTV DNA plasma levels in patients with a lower burden of IS: a first group of patients on tacrolimus monotherapy with trough levels lower than 5 ng/mL and normal liver function tests and a second group of tolerant patients. Individuals in the first group were checked for TTV a median of 12.5 years after transplant (range, 5.2-24.1 years), whereas in the tolerant group the viral load was analyzed a median of 21.4 years after transplant (range, 15.0-27.7 years) and 9.9 years (range, 8.8-15.0 years) after they fulfilled the criteria of tolerance. All patients in both groups had detectable viremia, but there were no significant differences between them. A last group of healthy individuals was included, all of them with detectable TTV DNA. No significant differences were found between the healthy controls and the patients of the prospective cohort before transplantation, nor with the longterm transplanted groups (Fig. 1) .
DiagnOstic anD preDictive value
The area under the receiver operating characteristic curve (AUROC) of the TTV DNA for the diagnosis of ACR at any time point was 0.772 (95% CI, 0.613-0.930). When we performed the same analysis only for episodes of moderate ACR, the AUROC was 0.869 (95% CI, 0.806-0.933). A cutoff value of 4.75 log 10 copies/mL yielded a sensitivity, specificity, and negative and positive predictive values of 100%, 77%, 100%, and 38%, respectively. For the diagnosis of CMV infection, the AUROC was 0.634 (95% CI, 0.531-0.737) and measured 0.860 (95% CI, 0.741-0.979) for CMV disease. For a cutoff value of 7.50 log 10 , sensitivity, specificity, and negative and positive predictive values were 80%, 84%, 98%, and 30%, respectively. We then evaluated the capacity of assessing plasma TTV DNA either before LT or during the first time points (week 1 and month 1) to predict subsequent rejection or onset of CMV infection, although the predictive ability was low (the AUROC ranged from 0.526 to 0.673 for the prediction of ACR and from 0.422 to 0.599 for the prediction of CMV).
Discussion
In the present manuscript, we have studied the levels of TTV DNA in LT recipients, assessing any correlation with ACR and infections. During the first months after LT, we found that TTV DNA levels were significantly lower during episodes of rejection, particularly during moderate episodes. In addition, TTV DNA plasma levels were significantly higher during episodes of CMV infection, and this difference was more pronounced in cases of CMV disease. Finally, TTV DNA levels were significantly higher in patients who received triple IS therapy. Indeed, these patients also presented more episodes of CMV infection. Overall, our results suggest that TTV DNA may be regarded as a surrogate of the state of IS during the first months after LT because it appears to be related to events clearly associated with IS.
TTV was discovered in 1997 and is highly prevalent in humans, although its pathogen capacity has not been clearly demonstrated. It seems to be associated with the immune status of the host. Thus, the hypothesis "the more immune suppressed, the higher the viremia" has been explored in several conditions, such as solid organ transplantation. Although TTV was initially thought to be the origin of liver damage in LT in the absence of other causes, studies that examined this hypothesis could not confirm it. (6, 7) Nevertheless, higher viremia was detected as the number of immunosuppressants increased, which was similarly observed in kidney and lung transplantation. Reports that involved less frequent sampling of TTV viral load than our study have shown a progressive increase in TTV viremia after transplantation, reaching a peak at month 3, followed by a gradual decline. (14) Regarding posttransplant events in LT, negative viremia before transplant has been associated with a higher incidence of rejection. (8) Similarly, low TTV viremia has been linked to a higher incidence of chronic allograft dysfunction in lung transplantation (15) and with antibody-mediated rejection in kidney transplantation. (16) Our results suggest a higher state of IS in patients who received triple IS: These patients presented significantly more episodes of CMV infection and had higher TTV DNA levels. In addition, all episodes of CMV disease were diagnosed in this group. Considering the absence of differences in the distribution of CMV donor-recipient serology mismatch and the relatively homogeneous trough levels of CNI between IS protocols, our results suggest that the use of MMF and induction with basiliximab is responsible for the higher state of IS observed in these patients. In fact, a higher risk of CMV infection has already been described in LT recipients receiving triple IS including MMF. (17) This immunosuppressant has also been associated with a more severe course of CMV infection and organ involvement. (18) In addition, Strassl et al. recently showed that an MMF dose 1.5 g or higher was the only IS therapy associated with a higher TTV viremia in kidney transplant recipients. (19) In contrast, in our cohort, patients with triple therapy did not present fewer episodes of rejection as might have been expected in light of the higher state of IS suggested. Nevertheless, immune mechanisms that lead to graft rejection are different than those that protect a host from infections and thus these 2 complications are not mutually exclusive. (20) Regarding the interaction between CMV and TTV, conflicting results have been reported in the literature. In the setting of allogeneic stem cell transplantation, Albert et al. showed an inverse association between TTV viremia and CMV infection, whereas no overall correlation was found between TTV DNA and CMV DNA. (21) Wohlfarth et al., in turn, showed a direct link between TTV DNA and CMV infection, as well as a linear correlation between the DNA of both viruses. (22) In the context of solid organ transplantation, a direct association between TTV and CMV infection has been reported in kidney transplantation, (19) whereas a report on lung recipients found no relationship. (23) These conflicting results may be partially explained by the inherent differences between the distinct types of organ transplantation, as well as the various types of immunosuppressive regimens used (and thus the different immunosuppressive burden). In addition, not
Original article | 309 only do the definitions of CMV infection used by these studies vary, but technical issues may also play a role because the assays and techniques used in the viral DNA detection for both TTV and CMV can differ. In addition, we did not find any association between recipient CMV serology and pretransplant TTV DNA, in contrast with a previous report involving healthy individuals. (24) After transplant, patients with negative serology (who presented a higher incidence of CMV infection) had a higher TTV DNA load, which was consistent with previous findings. (19) Although a potential association with CMV primoinfection after transplant has previously been hypothesized, our results showed that this difference was only significant in those patients who received triple IS, the same group that also presented a higher incidence of CMV infection. These results support the notion that TTV replication is related to immune status and is not directly associated with CMV.
Supporting a potential role as a marker of immune status, TTV viremia was associated with immunerelated events, being higher in CMV infections (higher IS) and lower in ACR (lower IS). Although, according to our results, assessing TTV DNA either before or during the first weeks after LT was not accurate for predicting the subsequent development of these complications, TTV DNA showed a very high sensitivity and negative predictive value in the diagnosis of such events, particularly in moderate ACR. Thus, TTV viremia could be regarded as a noninvasive tool to confidently rule out episodes of moderate ACR. It is clear that our results should be confirmed in prospective cohorts and need external validation in order to be considered for implementation in clinical practice. In addition, it may also be useful to explore whether the combination of TTV with other potential biomarkers related to immune status increases the diagnostic or predictive ability in the assessment of rejection following LT.
We also aimed to further investigate TTV viremia in longterm stable LT recipients. Interestingly, both in longterm transplanted patients with low IS burden and in tolerant patients, TTV prevalence was 100%, and no differences were found between these groups, either with healthy controls or with patients from the prospective cohort when assessed before LT. These results suggest that viremia does not vary in a significant way in the long term, when IS is less intense. The low levels of TTV DNA, which are comparable to healthy controls, seem consistent with a period after LT when the incidence of infections is similar to that of the general population. (25) As a study designed to assess a potential IS biomarker, ours has several limitations. First, the definition of immune status is still driven by the occurrence of clinical events, such as ACR or CMV infection, which act as clinical surrogates. Thus, there is not a true gold standard for immune status in transplant recipients, a limitation common to all IS biomarker studies. Second, it is clear that the development of the 2 events under study (ACR and CMV infection) can be impacted by circumstances different from those evaluated here. Third, time points of TTV evaluation after LT were arbitrarily chosen, and thus a more frequent assessment, or one involving other time intervals, could have a better diagnostic performance. It is important to highlight that this is the first study in which determination of TTV viral load after LT was performed with such high frequency. Finally, the wide distribution of TTV DNA at each time point could constitute an obstacle to better diagnostic accuracy, particularly in light of the relatively low prevalence of severe events related to markedly elevated or reduced IS (CMV disease and moderate to severe ACR). In turn, this is a study performed in a prospectively followed cohort at a single center, with homogeneous management of patients, and not only with a low threshold for performing liver biopsies but also including protocol biopsies. In addition, all results are consistent with TTV acting as a surrogate of IS status based on a sequence of clinical events. Finally, to date, this is the largest sample size of LT recipients in whom this virus has been studied.
In conclusion, TTV viremia seems clearly associated with immune-related events in LT recipients and may serve as a potential biomarker of immune status during the first months after transplant.
